AbbVie: HIV Infections trials

The registry lists 18 HIV Infections studies with AbbVie as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 4Phase 2 1Phase 3 4Phase 4 2No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-InfectionCompletedNCT03235349Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-InfectionCompletedNCT03222583Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)CompletedNCT02738138Phase 3Results posted
• A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionCompletedNCT01939197Phase 2/3Results posted
• Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) ProgramCompletedNCT01662336Results posted
• Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)CompletedNCT01383005Results posted
• Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infectionCompletedNCT01328158Results posted
• A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or LamivudineCompletedNCT01159743Results posted
• Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra TabletCompletedNCT01097655Results posted
• Kaletra in Combination With Antiretroviral AgentsCompletedNCT01076179Results posted
• Kaletra: Therapy With Double Protease InhibitorsCompletedNCT01075191Results posted
• Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)CompletedNCT04799353Phase 1
• Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)CompletedNCT04554966Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1CompletedNCT04223804Phase 1
• A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian FederationTerminatedNCT04138199
• Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of MidazolamCompletedNCT01827540Phase 1
• Safety and Efficacy of Kaletra in ARV Therapy Experienced PatientsCompletedNCT00648999Phase 4
• Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir ScoreCompletedNCT00234975Phase 4